Pharmacologic Strategies for the Prevention of Stroke in Patients With Atrial Fibrillation
- 151 Downloads
Stroke is a dreaded complication of atrial fibrillation. In the past, preventive therapy included aspirin and oral anticoagulation. Selected patients who are not suitable for oral anticoagulation may benefit from the addition of clopidogrel with aspirin. This combination, when compared with aspirin, offers a reduced risk of stroke at a cost of more major bleeding. We use this therapy in patients with atrial fibrillation who have unstable coronary syndromes or in patients who receive coronary artery stents who are not good candidates for “triple therapy” with aspirin, clopidogrel, and warfarin. The duration of therapy is tempered by many variables. In the case of coronary stents, we ask the interventionalist to consider a bare metal stent to shorten the duration of need for clopidogrel plus aspirin. After several months of combination therapy, we stop this therapy and begin warfarin therapy. Dabigatran is commercially available in the United States. In patients who have difficult to control International Normalized Ratio (INR) values or who do not wish to have regular coagulation monitoring, dabigatran offers a huge advantage. The benefit seems less if the INR is consistently within range. We are impressed with the superior reduction in stroke and systemic embolism with 150 mg of dabigatran twice daily compared to warfarin and also its low risk of intracranial hemorrhage. The results of clinical trials involving factor Xa agents are now being presented. How these agents fit into the marketplace remains to be seen but they will offer clinicians additional therapy for stroke prevention in atrial fibrillation.
KeywordsAtrial Fibrillation Warfarin Clopidogrel International Normalize Ratio Dabigatran
G. Flaker has received consulting fees from Sanofi Aventis and Bristol-Myers Squibb. He has received support for travel to meetings from Boehringer Ingelheim and Bristol-Myers Squibb, and his institution has received grant money from Boehringer Ingelheim and Bristol-Myers Squibb. R. Weachter reports no potential conflict of interest relevant to this article.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 12.Sadangara T, Sadanaga M, Ogawa S. Evidence that d-Dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. JACC. 2010;55:2225–31.Google Scholar
- 14.Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–12.PubMedCrossRefGoogle Scholar
- 16.2011 ACCF/AHA/HRS Focused Update on the Management of Patients with Atrial Fibrillation (Updating the 2006 Guideline)ACC/AHA guidelines. JACC 2011;57:223–42.Google Scholar
- 17.Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691–8.CrossRefGoogle Scholar
- 28.Freeman J, Zhu R, Owens DK et al. Cost Effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Annals Int Med 2010.Google Scholar
- 31.Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation unsuitable for vitamin K antagonists. New England J Feb 10, 2011;364:806–17.Google Scholar
- 32.The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: Rationale and design of the ROCKET AF study. Amer Heart J. 2010;159:340–7.CrossRefGoogle Scholar
- 33.ROCKET-AF. Presented at the American Heart Association meeting 2010.Google Scholar